Epileptic Seizures in Alzheimer's Disease: What Are the Implications of SANAD II?
- PMID: 34842191
- DOI: 10.3233/JAD-215154
Epileptic Seizures in Alzheimer's Disease: What Are the Implications of SANAD II?
Abstract
Epileptic seizures are increasingly recognized as part of the clinical phenotype of patients with Alzheimer's disease (AD). However, the evidence base on which to make treatment decisions for such patients is slim, there being no clear recommendation based on systematic review of the few existing studies of anti-seizure drugs in AD patients. Here the authors examine the potential implications for the treatment of seizures in AD of the results of the recently published SANAD II pragmatic study, which examined the effectiveness of levetiracetam, zonisamide, or lamotrigine in newly diagnosed focal epilepsy, and of valproate and levetiracetam in generalized and unclassifiable epilepsy.
Keywords: Alzheimer’s disease; epilepsy; seizures; treatment.
Comment on
-
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
-
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
